Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
We’re excited to share our latest report on gene, cell, and rna therapies with The American Society of Gene and Cell Therapy (ASGCT). This Q1 2023 report calls out important updates and changes within the gene, cell, and rna therapy landscape.
Highlights of the report:
For the first time since Q2 2022, there were no new first approvals for gene therapies; however, Q1 2023 did see new RNA therapy and non-genetically modified cell therapy approvals
Anticancer and rare diseases are the top two targeted therapeutic areas for pipeline gene, non genetically modified, and RNA therapies
Overall dealmaking by advanced molecule companies in Q1 2023 was virtually flat
vs. Q4 2022, but start up financing rebounded
When you work with our Custom Intelligence team you gain access to the deep subject matter expertise of a global network of over 400 pharma and medtech industry experts, underpinned by the market-leading data of the Citeline product suite.
Your project lead will work in collaboration with you to understand your requirements, assign dedicated consultant support, and arrange analyst research to deliver actionable solutions in accordance with your business goals.
Whether you lack available staff, want an objective perspective, or need outside expertise, our team assesses your needs and provides in-depth research, expert insights, and innovative strategies that lead to success.
Ly Specialises in
22+ years of experience
Connecticut , USA
Amanda Specialises in
23+ years of experience
Shardha Specialises in
We’re excited to share our latest report on gene, cell, and RNA therapies with The American Society of Gene and Cell Therapy (ASGCT). This Q4 report calls out important updates and changes within the gene, cell, and RNA therapy landscape.
We’re excited to share our latest report on gene, cell, and RNA therapies with The American Society of Gene and Cell Therapy (ASGCT). This Q3 report calls out important updates and changes within the gene, cell, and RNA therapy landscape.
We’re excited to share our latest report on gene, cell, and RNA therapies with The American Society of Gene and Cell Therapy (ASGCT). This Q2 report calls out important updates and changes within the gene, cell, and RNA therapy landscape.
We’re excited to share our latest report on gene, cell, and RNA therapies with The American Society of Gene and Cell Therapy (ASGCT). This Q1 report calls out important updates and changes within the gene, cell, and RNA therapy landscape.
We have received your request and we will get back to you soon.
